These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 17628435)

  • 1. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study.
    Sumiyoshi T; Park S; Jayathilake K; Roy A; Ertugrul A; Meltzer HY
    Schizophr Res; 2007 Sep; 95(1-3):158-68. PubMed ID: 17628435
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Enhancement of cognitive performance in schizophrenia by addition of tandospirone to neuroleptic treatment.
    Sumiyoshi T; Matsui M; Nohara S; Yamashita I; Kurachi M; Sumiyoshi C; Jayathilake K; Meltzer HY
    Am J Psychiatry; 2001 Oct; 158(10):1722-5. PubMed ID: 11579010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of cognitive dysfunction in chronic schizophrenia by augmentation of atypical antipsychotics with buspirone, a partial 5-HT(1A) receptor agonist.
    Piskulić D; Olver JS; Maruff P; Norman TR
    Hum Psychopharmacol; 2009 Aug; 24(6):437-46. PubMed ID: 19637398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Adjunctive azapirone for schizophrenia: A meta-analysis of randomized, double-blind, placebo-controlled trials.
    Zheng W; Li XH; Cai DB; Yang XH; Ungvari GS; Ng CH; Ning YP; Xiang YT
    Eur Neuropsychopharmacol; 2018 Jan; 28(1):149-158. PubMed ID: 29174529
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-treatment of buspirone with atypical antipsychotic drugs (AAPDs) improved neurocognitive function in chronic schizophrenia.
    Wang Y; Yang X; Song X; Zhao L; Wei J; Wang J; Tian H; Zheng C; Wei M; Wang Q; Guo W; Deng W; Li T; Ma X
    Schizophr Res; 2019 Jul; 209():135-140. PubMed ID: 31101513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A double-blind study of combination of clozapine with risperidone in patients with schizophrenia: effects on cognition.
    Akdede BB; Anil Yağcioğlu AE; Alptekin K; Turgut TI; Tümüklü M; Yazici MK; Jayathilake K; Tunca Z; Göğüş A; Meltzer HY
    J Clin Psychiatry; 2006 Dec; 67(12):1912-9. PubMed ID: 17194269
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A double-blind, randomized, and placebo-controlled trial of buspirone added to risperidone in patients with chronic schizophrenia.
    Ghaleiha A; Noorbala AA; Farnaghi F; Hajiazim M; Akhondzadeh S
    J Clin Psychopharmacol; 2010 Dec; 30(6):678-82. PubMed ID: 21105281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Interest of a new instrument to assess cognition in schizophrenia: The Brief Assessment of Cognition in Schizophrenia (BACS)].
    Bralet MC; Navarre M; Eskenazi AM; Lucas-Ross M; Falissard B
    Encephale; 2008 Dec; 34(6):557-62. PubMed ID: 19081451
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of tandospirone, a serotonin(1A) agonist, on memory function in schizophrenia.
    Sumiyoshi T; Matsui M; Yamashita I; Nohara S; Kurachi M; Uehara T; Sumiyoshi S; Sumiyoshi C; Meltzer HY
    Biol Psychiatry; 2001 May; 49(10):861-8. PubMed ID: 11343682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A 12-week, double-blind, placebo-controlled trial of donepezil as an adjunct to haloperidol for treating cognitive impairments in patients with chronic schizophrenia.
    Lee BJ; Lee JG; Kim YH
    J Psychopharmacol; 2007 Jun; 21(4):421-7. PubMed ID: 17092979
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized double-blind comparison of ziprasidone vs. clozapine for cognition in patients with schizophrenia selected for resistance or intolerance to previous treatment.
    Harvey PD; Sacchetti E; Galluzzo A; Romeo F; Gorini B; Bilder RM; Loebel AD
    Schizophr Res; 2008 Oct; 105(1-3):138-43. PubMed ID: 18077136
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Augmentation of antipsychotic drug action by azapirone 5-HT1A receptor partial agonists: a meta-analysis.
    Kishi T; Meltzer HY; Iwata N
    Int J Neuropsychopharmacol; 2013 Jul; 16(6):1259-66. PubMed ID: 23551924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Galantamine for the treatment of cognitive impairments in people with schizophrenia.
    Buchanan RW; Conley RR; Dickinson D; Ball MP; Feldman S; Gold JM; McMahon RP
    Am J Psychiatry; 2008 Jan; 165(1):82-9. PubMed ID: 17986678
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cognitive and psychomotor effects of risperidone in schizophrenia and schizoaffective disorder.
    Houthoofd SA; Morrens M; Sabbe BG
    Clin Ther; 2008 Sep; 30(9):1565-89. PubMed ID: 18840365
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial.
    Akhondzadeh S; Mohammadi N; Noroozian M; Karamghadiri N; Ghoreishi A; Jamshidi AH; Forghani S
    Schizophr Res; 2009 Feb; 107(2-3):206-12. PubMed ID: 18789844
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cognitive effects of adjunctive 24-weeks Rivastigmine treatment to antipsychotics in schizophrenia: a randomized, placebo-controlled, double-blind investigation.
    Sharma T; Reed C; Aasen I; Kumari V
    Schizophr Res; 2006 Jul; 85(1-3):73-83. PubMed ID: 16797163
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Translating the N-methyl-D-aspartate receptor antagonist model of schizophrenia to treatments for cognitive impairment in schizophrenia.
    Meltzer HY; Rajagopal L; Huang M; Oyamada Y; Kwon S; Horiguchi M
    Int J Neuropsychopharmacol; 2013 Nov; 16(10):2181-94. PubMed ID: 24099265
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of cognitive impairment in early psychosis: a comparison of risperidone and haloperidol in a large long-term trial.
    Harvey PD; Rabinowitz J; Eerdekens M; Davidson M
    Am J Psychiatry; 2005 Oct; 162(10):1888-95. PubMed ID: 16199835
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A 12-week, double-blind, placebo-controlled trial of galantamine adjunctive treatment to conventional antipsychotics for the cognitive impairments in chronic schizophrenia.
    Lee SW; Lee JG; Lee BJ; Kim YH
    Int Clin Psychopharmacol; 2007 Mar; 22(2):63-8. PubMed ID: 17293705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled trial of glycine added to clozapine in schizophrenia.
    Evins AE; Fitzgerald SM; Wine L; Rosselli R; Goff DC
    Am J Psychiatry; 2000 May; 157(5):826-8. PubMed ID: 10784481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.